Literature DB >> 31558239

Acquired BRAF V600E Mutation Mediated Resistance to Osimertinib and Responded to Osimertinib, Dabrafenib, and Trametinib Combination Therapy.

Yihua Huang1, Jiadi Gan1, Kunbin Guo2, Yangyang Deng3, Wenfeng Fang4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31558239     DOI： 10.1016/j.jtho.2019.05.040

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  8 in total

1.  Impressive response to dabrafenib, trametinib, and osimertinib in a metastatic EGFR-mutant/BRAF V600E lung adenocarcinoma patient.

Authors:  Maurício Fernando Silva Almeida Ribeiro; Franciele Hinterholz Knebel; Fabiana Bettoni; Rodrigo Saddi; Karina Perez Sacardo; Felipe Sales Nogueira Amorim Canedo; João Victor Machado Alessi; Andrea Kazumi Shimada; José Flávio Gomes Marin; Anamaria Aranha Camargo; Artur Katz
Journal:  NPJ Precis Oncol       Date:  2021-02-12

Review 2.  Cell Line Models for Acquired Resistance to First-Line Osimertinib in Lung Cancers-Applications and Limitations.

Authors:  Shuta Ohara; Kenichi Suda; Tetsuya Mitsudomi
Journal:  Cells       Date:  2021-02-09       Impact factor: 6.600

3.  High Incidence of C797S Mutation in Patients With Long Treatment History of EGFR Tyrosine Kinase Inhibitors Including Osimertinib.

Authors:  Atsushi Osoegawa; Masafumi Yamaguchi; Tomomi Nakamura; Ryotaro Morinaga; Kentaro Tanaka; Kosuke Kashiwabara; Takashi Miura; Takayuki Suetsugu; Taishi Harada; Tatsuma Asoh; Kenichi Taguchi; Kazuki Nabeshima; Junji Kishimoto; Kazuko Sakai; Kazuto Nishio; Kenji Sugio
Journal:  JTO Clin Res Rep       Date:  2021-05-14

4.  Clonal dynamics of BRAF-driven drug resistance in EGFR-mutant lung cancer.

Authors:  Diana Schaufler; David F Ast; Hannah L Tumbrink; Nima Abedpour; Lukas Maas; Ayla E Schwäbe; Inga Spille; Stefanie Lennartz; Jana Fassunke; Mihaela Aldea; Benjamin Besse; David Planchard; Lucia Nogova; Sebastian Michels; Carsten Kobe; Thorsten Persigehl; Theresa Westphal; Sophia Koleczko; Rieke Fischer; Jan-Phillip Weber; Janine Altmüller; Roman K Thomas; Sabine Merkelbach-Bruse; Oliver Gautschi; Laura Mezquita; Reinhard Büttner; Jürgen Wolf; Martin Peifer; Johannes Brägelmann; Matthias Scheffler; Martin L Sos
Journal:  NPJ Precis Oncol       Date:  2021-12-17

5.  Combined targeting of EGFR and BRAF triggers regression of osimertinib resistance by using osimertinib and vemurafenib concurrently in a patient with heterogeneity between different lesions.

Authors:  Mengyao Sun; Xu Wang; Yinghui Xu; Chao Sun; Ye Guo; Shi Qiu; Renshan Zhao; Wenhao Zhu; Kewei Ma
Journal:  Thorac Cancer       Date:  2021-12-27       Impact factor: 3.500

6.  EGFR/BRAF/MEK co-inhibition for EGFR-mutated lung adenocarcinoma patients with an acquired BRAFV600E mutation: a case report and review of literature.

Authors:  Ran Zeng; Lifeng Luo; Xianwen Sun; Zhiyao Bao; Wei Du; Ranran Dai; Wei Tang; Beili Gao; Yi Xiang
Journal:  Cancer Drug Resist       Date:  2021-12-01

Review 7.  Acquired Mechanisms of Resistance to Osimertinib-The Next Challenge.

Authors:  Alejandro Ríos-Hoyo; Laura Moliner; Edurne Arriola
Journal:  Cancers (Basel)       Date:  2022-04-12       Impact factor: 6.575

Review 8.  The Evolution of BRAF Activation in Non-Small-Cell Lung Cancer.

Authors:  Longyao Zhang; Linpeng Zheng; Qiao Yang; Jianguo Sun
Journal:  Front Oncol       Date:  2022-07-13       Impact factor: 5.738
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.